Dehydroepiandrosterone prevents the aggregation of platelets obtained from postmenopausal women with type 2 diabetes mellitus through the activation of the PKC/eNOS/NO pathway

Hormone and Metabolic Research

Volumn 44, Issue 8, 2012, Pages 625-631

  Munoz Y C ^a,b   Gomez, G I ^a   Moreno, M ^c   Solis, C L ^b   Valladares, L E ^d   Velarde, V ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b Asociación de Diabéticos de Chile ADICH   (Chile)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^d UNIVERSITY OF CHILE   (Chile)

Author keywords

atherothrombosis; cardioprotection; steroid hormone

Indexed keywords

ATENOLOL; CYCLIC GMP; ENALAPRIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLIBENCLAMIDE; LNG NITROARGININE; METFORMIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PRASTERONE; PROTEIN KINASE C; ROTTLERIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA;

BLOOD PLATELETS; CYCLIC GMP; DEHYDROEPIANDROSTERONE; DIABETES MELLITUS, TYPE 2; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; HUMANS; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; PHOSPHOSERINE; PLATELET AGGREGATION; POSTMENOPAUSE; PROTEIN KINASE C-DELTA; SIGNAL TRANSDUCTION;

EID: 84863784135     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0032-1309056     Document Type: Article

References (56)

1. Vokonas P S, Kannel W B. Diabetes mellitus and coronary heart disease in the elderly. Clin Geriatr Med: 1996; 12 69 78 (Pubitemid 26073081)
2. Nathan D M. Long-term complications of diabetes mellitus. N Engl J Med: 1993; 328 1676 1685 (Pubitemid 23157351)
3. Beckman J A, Creager M A, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA: 2002; 287 2570 2581 (Pubitemid 34517204)
4. Nestler J E, Clore J N, Blackard W G. Metabolism and actions of dehydroepiandrosterone in humans. J Steroid Biochem Mol Biol: 1991; 40 599 605
5. Labrie F. DHEA, important source of sex steroids in men and even more in women. Prog Brain Res: 2010; 182 97 148
6. Labrie F, Luu-The V, Bélanger A, Lin S X, Simard J, Pelletier G, Labrie C. Is dehydroepiandrosterone a hormone? J Endocrinol: 2005; 187 169 196
7. Labrie F, Luu-The V, Labrie C, Bélanger A, Simard J, Lin S X, Pelletier G. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev: 2003; 24 152 182 (Pubitemid 36515283)
8. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Kurioka S, Yano S, Sugimoto T. Serum DHEA-S level is associated with the presence of atherosclerosis in postmenopausal women with type 2 diabetes mellitus. Endocr J: 2008; 55 667 675
9. Mitchell L E, Sprecher D L, Borecki I B, Rice T, Laskarzewski P M, Rao D C. Evidence for an association between dehydroepiandrosterone sulfate and nonfatal, premature myocardial infarction in males. Circulation: 1994; 89 89 93 (Pubitemid 24026476)
10. Alexandersen P, Haarbo J, Christiansen C. The relationship of natural androgens to coronary heart disease in males: a review. Atherosclerosis: 1996; 125 1 13 (Pubitemid 26267117)
11. Panjari M, Davis S R. DHEA for postmenopausal women: a review of the evidence. Maturitas: 2010; 66 172 179
12. Colwell J A, Nesto R W. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care: 2003; 26 2181 2188
13. Vinik A I, Erbas T, Park T S, Nolan R, Pittenger G L. Platelet dysfunction in type 2 diabetes. Diabetes Care: 2001; 24 1476 1485 (Pubitemid 33716440)
14. Tschope D, Rosen P, Gries F A. Increase in the cytosolic concentration of calcium in platelets of diabetics type II. Thromb Res: 1991; 62 421 428
15. Martina V, Bruno G A, Trucco F, Zumpano E, Tagliabue M, Di Bisceglie C, Pescarmona G. Platelet cNOS activity is reduced in patients with IDDM and NIDDM. Thromb Haemost: 1998; 79 520 522 (Pubitemid 28120783)
16. Ferroni P, Basili S, Falco A, Davì G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost: 2004; 2 1282 1291 (Pubitemid 40186123)
17. Hamet P, Skuherska R, Pang S C, Tremblay J. Abnormalities of platelet function in hypertension and diabetes. Hypertension: 1985; 7 II135 II142
18. Tschoepe D, Roesen P, Kaufmann L, Schauseil S, Kehrel B, Ostermann H, Gries F A. Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur J Clin Invest: 1990; 20 166 170 (Pubitemid 20126655)
19. Radomski M W, Palmer R M, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet: 1987; 2 1057 1058 (Pubitemid 17154788)
20. Freedman J E, Loscalzo J, Barnard M R, Alpert C, Keaney J F, Michelson A D. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest: 1997; 100 350 356 (Pubitemid 27349081)
21. Radomski M W, Palmer R M, Moncada S. An l -arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA: 1990; 87 5193 5197
22. Rabini R A, Staffolani R, Fumelli P, Mutus B, Curatola G, Mazzanti L. Decreased nitric oxide synthase activity in platelets from IDDM and NIDDM patients. Diabetologia: 1998; 41 101 104 (Pubitemid 28105748)
23. Chirkov Y, Tyshchuk I A, Severina I S. Guanylate cyclase in human platelets with different aggregability. Experientia: 1990; 46 697 699 (Pubitemid 20216635)
24. Ikeda H, Takajo Y, Murohara T, Ichiki K, Adachi H, Haramaki N, Katoh A, Imaizumi T. Platelet-derived nitric oxide and coronary risk factors. Hypertension: 2000; 35 904 907 (Pubitemid 30303948)
25. Mundell S J, Jones M L, Hardy A R, Barton J F, Beaucourt S M, Conley P B, Poole A W. Distinct roles for protein kinase C isoforms in regulating platelet purinergic receptor function. Mol Pharmacol: 2006; 70 1132 1142 (Pubitemid 44268470)
26. Harper M T, Poole A W. Isoform-specific functions of protein kinase C: the platelet paradigm. Biochem Soc Trans: 2007; 35 1005 1008 (Pubitemid 350206414)
27. Jesse R L, Loesser K, Eich D M, Qian Y Z, Hess M L, Nestler J E. Dehydro-epi-androsterone inhibits human platelet aggregation in vitro and in vivo. Ann N Y Acad Sci: 1995; 774 281 290 (Pubitemid 26140377)
28. Formoso G, Chen H, Kim J A, Montagnani M, Consoli A, Quon M J. Dehydroepiandrosterone mimics acute actions of insulin to stimulate production of both nitric oxide and endothelin 1 via distinct phosphatidylinositol 3-kinase- and mitogen-activated protein kinase-dependent pathways in vascular endothelium. Mol Endocrinol: 2006; 20 1153 1163
29. Matthews D R, Hosker J P, Rudenski A S, Naylor B A, Treacher D F, Turner R C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia: 1985; 28 412 419 (Pubitemid 15018832)
30. Mustard J F, Perry D W, Ardlie N G, Packham M A. Preparation of suspensions of washed platelets from humans. Br J Haematol: 1972; 22 193 204
31. Panes O, Matus V, Sáez C G, Quiroga T, Pereira J, Mezzano D. Human platelets synthesize and express functional tissue factor. Blood: 2007; 109 5242 5250 (Pubitemid 46890544)
32. Born G V. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature: 1962; 194 927 929
33. Liu D, Dillon J S. Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3). J Biol Chem: 2002; 277 21379 21388 (Pubitemid 34952278)
34. Simoncini T, Mannella P, Fornari L, Varone G, Caruso A, Genazzani A R. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology: 2003; 144 3449 3455 (Pubitemid 36904421)
35. Hirafuji M, Nezu A, Shinoda H, Minami M. Involvement of platelet cyclic GMP but not cyclic AMP suppression in leukocyte-dependent platelet adhesion to endothelial cells induced by platelet-activating factor in vitro. Br J Pharmacol: 1996; 117 299 304 (Pubitemid 26030283)
36. Moore P K, al-Swayeh O A, Chong N W, Evans R A, Gibson A. L-NG-nitro arginine (L-NOARG), a novel, L-arginine-reversible inhibitor of endothelium-dependent vasodilatation in vitro. Br J Pharmacol: 1990; 99 408 412 (Pubitemid 20147541)
37. da Silva C G, Specht A, Wegiel B, Ferran C, Kaczmarek E. Mechanism of purinergic activation of endothelial nitric oxide synthase in endothelial cells. Circulation: 2009; 119 871 879
38. Gschwendt M, Müller H J, Kielbassa K, Zang R, Kittstein W, Rincke G, Marks F. Rottlerin, a novel protein kinase inhibitor. Biochem Biophys Res Commun: 1994; 199 93 98 (Pubitemid 24179919)
39. Sugimoto K, Fujii S, Takemasa T, Yamashita K. Detection of intracellular nitric oxide using a combination of aldehyde fixatives with 4,5- diaminofluorescein diacetate. Histochem Cell Biol: 2000; 113 341 347 (Pubitemid 30341301)
40. Cooper M E. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia: 2001; 44 1957 1972 (Pubitemid 33124041)
41. Libby P. Inflammation in atherosclerosis. Nature: 2002; 420 868 874 (Pubitemid 36019640)
42. Schafer A, Wiesmann F, Neubauer S, Eigenthaler M, Bauersachs J, Channon K M. Rapid regulation of platelet activation in vivo by nitric oxide. Circulation: 2004; 109 1819 1822 (Pubitemid 38509113)
43. Hayashi T, Matsui-Hirai H, Miyazaki-Akita A, Fukatsu A, Funami J, Ding Q F, Kamalanathan S, Hattori Y, Ignarro L J, Iguchi A. Endothelial cellular senescence is inhibited by nitric oxide: implications in atherosclerosis associated with menopause and diabetes. Proc Natl Acad Sci USA: 2006; 103 17018 17023 (Pubitemid 44737370)
44. Tchernof A, Labrie F. Dehydroepiandrosterone, obesity and cardiovascular disease risk: a review of human studies. Eur J Endocrinol: 2004; 151 1 14 (Pubitemid 39117360)
45. Dhatariya K, Bigelow M L, Nair K S. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes: 2005; 54 765 769 (Pubitemid 40322080)
46. Hsu W C. Consequences of delaying progression to optimal therapy in patients with type 2 diabetes not achieving glycemic goals. South Med J: 2009; 102 67 76
47. de Lemos J A, Zirlik A, Schönbeck U, Varo N, Murphy S A, Khera A, McGuire D K, Stanek G, Lo H S, Nuzzo R, Morrow D A, Peshock R, Libby P. Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol: 2005; 25 2192 2196 (Pubitemid 41416320)
48. Osuka K, Watanabe Y, Usuda N, Atsuzawa K, Aoshima C, Yamauchi K, Takayasu M, Yoshida J. Phosphorylation of neuronal nitric oxide synthase at Ser847 in the nucleus intermediolateralis after spinal cord injury in mice. Neuroscience: 2007; 145 241 247 (Pubitemid 46227706)
49. Li J, Yang C, Han S, Zu P, Wu J, Xu Q, Fang L. Increased phosphorylation of neurogranin in the brain of hypoxic preconditioned mice. Neurosci Lett: 2006; 391 150 153 (Pubitemid 41736190)
50. Gachet C. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs. Pharmacol Ther: 2005; 108 180 192 (Pubitemid 41528788)
51. Zuccollo A, Shi C, Mastroianni R, Maitland-Toolan K A, Weisbrod R M, Zang M, Xu S, Jiang B, Oliver-Krasinski J M, Cayatte A J, Corda S, Lavielle G, Verbeuren T J, Cohen R A. The thromboxane A2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus. Circulation: 2005; 112 3001 3008 (Pubitemid 41612304)
52. Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res: 2006; 99 1293 1304 (Pubitemid 44949665)
53. Reid H M, Kinsella B T. The alpha, but not the beta, isoform of the human thromboxane A2 receptor is a target for nitric oxide-mediated desensitization. Independent modulation of Tp alpha signaling by nitric oxide and prostacyclin. J Biol Chem: 2003; 278 51190 51202 (Pubitemid 38020356)
54. Tolhurst G, Vial C, Léon C, Gachet C, Evans R J, Mahaut-Smith M P. Interplay between P2Y(1), P2Y(12), and P2X(1) receptors in the activation of megakaryocyte cation influx currents by ADP: evidence that the primary megakaryocyte represents a fully functional model of platelet P2 receptor signaling. Blood: 2005; 106 1644 1651 (Pubitemid 41208577)
55. Halbrugge M, Walter U. Purification of a vasodilator-regulated phosphoprotein from human platelets. Eur J Biochem: 1989; 185 41 50 (Pubitemid 19262320)
56. Pula G, Schuh K, Nakayama K, Nakayama K I, Walter U, Poole A W. PKC delta regulates collagen-induced platelet aggregation through inhibition of VASP-mediated filopodia formation. Blood: 2006; 108 4035 4044 (Pubitemid 44913272)